United States - English - NLM (National Library of Medicine)

baxter healthcare corporation - ceftriaxone sodium (unii: 023z5br09k) (ceftriaxone - unii:75j73v1629) - ceftriaxone sodium 1 g

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - ceftriaxone sodium (unii: 023z5br09k) (ceftriaxone - unii:75j73v1629) - ceftriaxone 1 g

Australia - English - Department of Health (Therapeutic Goods Administration)

petrus pharmaceuticals pty ltd - ceftriaxone -

Australia - English - Department of Health (Therapeutic Goods Administration)

petrus pharmaceuticals pty ltd - ceftriaxone -

Australia - English - Department of Health (Therapeutic Goods Administration)

petrus pharmaceuticals pty ltd - ceftriaxone -

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - ceftriaxone sodium, quantity: 596.5 mg (equivalent: ceftriaxone, qty 500 mg) - injection, powder for - excipient ingredients: - treatment of the following infections when caused by susceptible aerobic organisms. lower respiratory tract infections. caused by strep. pneumoniae, streptococcus sp. (excluding enterococci), methicillin sensitive staph. aureus, h. influenzae, h. parainfluenzae, klebsiella sp. (including k. pneumoniae), e. coli, e. aerogenes, p. mirabilis and serratia marcescens. skin and skin structure infections. caused by methicillin sensitive staph. aureus, methicillin sensitive staph. epidermidis, streptococcus group b, streptococcus group g, strep. pyogenes, strep. viridans, streptococcus sp. (excluding enterococci), peptostreptococcus sp., e. coli, e. cloacae, klebsiella sp . (including k. pneumoniae and k. oxytoca), p. mirabilis, m morganii and s. marcescens. urinary tract infections (complicated and uncomplicated). caused by e. coli, p. mirabilis, p. vulgaris, m morganii and klebsiella sp. (including k. pneumoniae). uncomplicated gonorrhoea (cervical/ urethral and rectal). caused by n. gonorrhoeae, including both pencillinase and nonpenicillinase producing strains. bacterial septicaemia. caused by strep. pneumoniae, e. coli and h. influenzae. bone infections. caused by methicillin sensitive staph. aureus, methicillin sensitive staph. epidermidis, streptococcus group b, strep. pneumoniae, streptococcus sp. (excluding enterococci), e. coli, enterobacter sp., p. mirabilis and k. pneumoniae. joint infections. caused by methicillin sensitive staph. aureus, strep. pneumoniae, streptococcus sp. (excluding enterococci), e. coli, p. mirabilis, k. pneumoniae and enterobacter sp. meningitis. the initial treatment, as a single agent, of meningitis in children and immunocompetent adults when presumed or proven to be caused by h. influenzae type b, n. meningitidis, strep. pneumoniae or enterobacteriaceae pending culture and sensitivity results. surgical prophylaxis. the preoperative administration of a single 1 g dose of ceftriaxone may reduce the incidence of postoperative infections in patients undergoing vaginal or abdominal hysterectomy or cholecystectomy in high risk patients, surgical procedures which are classified as contaminated or potentially contaminated, and patients undergoing coronary artery bypass surgery. although ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo controlled trials have been conducted. susceptibility testing. before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. therapy may be instituted prior to obtaining results of susceptibility testing.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - ceftriaxone sodium, quantity: 298.3 mg (equivalent: ceftriaxone, qty 250 mg) - injection, powder for - excipient ingredients: - treatment of the following infections when caused by susceptible aerobic organisms. lower respiratory tract infections. caused by strep. pneumoniae, streptococcus sp. (excluding enterococci), methicillin sensitive staph. aureus, h. influenzae, h. parainfluenzae, klebsiella sp. (including k. pneumoniae), e. coli, e. aerogenes, p. mirabilis and serratia marcescens. skin and skin structure infections. caused by methicillin sensitive staph. aureus, methicillin sensitive staph. epidermidis, streptococcus group b, streptococcus group g, strep. pyogenes, strep. viridans, streptococcus sp. (excluding enterococci), peptostreptococcus sp., e. coli, e. cloacae, klebsiella sp . (including k. pneumoniae and k. oxytoca), p. mirabilis, m morganii and s. marcescens. urinary tract infections (complicated and uncomplicated). caused by e. coli, p. mirabilis, p. vulgaris, m morganii and klebsiella sp. (including k. pneumoniae). uncomplicated gonorrhoea (cervical/ urethral and rectal). caused by n. gonorrhoeae, including both pencillinase and nonpenicillinase producing strains. bacterial septicaemia. caused by strep. pneumoniae, e. coli and h. influenzae. bone infections. caused by methicillin sensitive staph. aureus, methicillin sensitive staph. epidermidis, streptococcus group b, strep. pneumoniae, streptococcus sp. (excluding enterococci), e. coli, enterobacter sp., p. mirabilis and k. pneumoniae. joint infections. caused by methicillin sensitive staph. aureus, strep. pneumoniae, streptococcus sp. (excluding enterococci), e. coli, p. mirabilis, k. pneumoniae and enterobacter sp. meningitis. the initial treatment, as a single agent, of meningitis in children and immunocompetent adults when presumed or proven to be caused by h. influenzae type b, n. meningitidis, strep. pneumoniae or enterobacteriaceae pending culture and sensitivity results. surgical prophylaxis. the preoperative administration of a single 1 g dose of ceftriaxone may reduce the incidence of postoperative infections in patients undergoing vaginal or abdominal hysterectomy or cholecystectomy in high risk patients, surgical procedures which are classified as contaminated or potentially contaminated, and patients undergoing coronary artery bypass surgery. although ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo controlled trials have been conducted. susceptibility testing. before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. therapy may be instituted prior to obtaining results of susceptibility testing.

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

fresenius kabi sa-nv - ceftriaxone disodium - eq. ceftriaxone 1000 mg - powder for solution for injection/infusion - 1 g - ceftriaxone (di)sodium - ceftriaxone

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

fresenius kabi sa-nv - ceftriaxone disodium - eq. ceftriaxone 2000 mg - powder for solution for infusion - 2 g - ceftriaxone (di)sodium - ceftriaxone

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

viatris gx bv-srl - ceftriaxone disodium 2158,54 mg - eq. ceftriaxone 2000 mg - powder for solution for infusion - 2 g - ceftriaxone (di)sodium - ceftriaxone